{"id":"W1964185052","doi":"10.1007/s10637-010-9399-1","title":"A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Population; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Doxorubicin; Chemotherapy; Adenocarcinoma; Surgery; Esophagus; Progressive disease; Oncology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001638842,0.001728465,0.002809532,0.000560575,0.0005252198,0.00101131,0.0008173796,0.001853489,0.002538845],"category_scores_gemma":[0.0009597766,0.0007431266,0.001628054,0.0005184307,0.001126302,0.001194969,0.0003505447,0.00406209,0.0006965021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000985028,"about_ca_system_score_gemma":0.001648521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001991031,"about_ca_topic_score_gemma":0.004082134,"domain_scores_codex":[0.9995239,0.0002038902,0.00002058476,0.00008632323,0.00003439259,0.0001308296],"domain_scores_gemma":[0.9994155,0.0001205011,0.00006419541,0.00006261916,0.00004417647,0.0002929547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6579775,0.1498496,0.005368709,0.0008884178,0.001453731,0.0006002564,0.0006845782,0.00434043,0.08744194,0.0005473616,0.003972153,0.08687536],"study_design_scores_gemma":[0.4159316,0.5687101,0.005893917,0.00001814295,0.0004701196,0.0002170659,0.00009425628,0.001230945,0.005242144,0.0001182313,0.002036991,0.00003650075],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947649,0.001186933,0.000474349,0.0004107038,0.0001390159,0.00150657,0.0004893474,0.00004880397,0.0009792768],"genre_scores_gemma":[0.9902954,0.001679687,0.001374964,0.0006763735,0.0001765793,0.001814689,0.001430121,0.00003718285,0.002514932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002809532,"threshold_uncertainty_score":0.008667171,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007041558149605497,"score_gpt":0.2578805014282209,"score_spread":0.2508389432786154,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}